-
-
-
-
-
-
-
Myriad Genetics Reports Third Quarter 2025 Financial Results; Reiterates 2025 Financial Guidance Following Continued Solid Execution
-
-
-
-
-
-
-
Myriad Genetics Reports Third Quarter 2024 Financial Results; Updates 2024 Financial Guidance
-
-
-
-
-
-
-
Myriad Genetics (MYGN) Announces CFO Resignation
-
-
-
-
-
-
-
Myriad Genetics Reports Fourth Quarter Financial Results; Fourth Quarter Revenue of $177.8 Million Grew 11% Year-Over-Year Driven by 16% Growth in Hereditary Cancer Volumes and 23% Growth in GeneSight
-
-
-
-
-
-
-
Myriad Genetics Reports Second Quarter Financial Results
-
-
-
-
-
-
-
Myriad Genetics Reports First Quarter Revenue and Reiterates Guidance for 2022
-
-
-
-
-
-
-
Myriad Genetics Receives FDA Approval of BRACAnalysis® CDx as a Companion Diagnostic for Lynparza® in Early Breast Cancer
-
1,173,829 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

